文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克复苏中早期使用去甲肾上腺素(CENSER):一项随机试验

Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2019-01-01
一句话结论在脓毒性休克伴低血压成人中,早期低剂量去甲肾上腺素使6小时休克控制率从48.4%升至76.1%,但28天死亡率无显著差异。

CENSER是一项在泰国Siriraj医院开展的单中心、随机、双盲、安慰剂对照II期试验,纳入310例脓毒症伴低血压成人,随机分为早期去甲肾上腺素组(n=155)和标准治疗组(n=155)。主要终点为诊断后6小时内休克控制率(平均动脉压≥65 mm Hg且连续2小时尿量≥0.5 ml/kg/h,或血清乳酸较基线下降≥10%)。早期去甲肾上腺素组6小时休克控制率显著高于标准治疗组(76.1% vs 48.4%,P<0.001),28天死亡率无显著差异(15.5% vs 21.9%,P=0.15)。早期去甲肾上腺素组心源性肺水肿(14.4% vs 27.7%,P=0.004)和新发心律失常(11% vs 20%,P=0.03)发生率更低。作者认为进一步研究前不应将此方法引入临床复苏实践。

要点

  • 脓毒症伴低血压成人早期使用低剂量去甲肾上腺素,6小时休克控制率76.1% vs 标准治疗48.4%(P<0.001)。
  • 早期去甲肾上腺素组从急诊室到达至给药的中位时间显著更短(93 min vs 192 min,P<0.001)。
  • 28天死亡率两组无显著差异:早期去甲肾上腺素组15.5% vs 标准治疗组21.9%(P=0.15)。
  • 早期去甲肾上腺素组心源性肺水肿(14.4% vs 27.7%,P=0.004)和新发心律失常(11% vs 20%,P=0.03)发生率更低。
  • 作者结论:早期去甲肾上腺素与6小时休克控制率增加显著相关,但将此方法引入临床复苏实践前需进一步研究。

适用人群与场景

  • 纳入:在泰国Siriraj医院就诊的310例脓毒症伴低血压成人。

诊断标准与关键阈值

  • 休克控制定义:平均动脉压≥65 mm Hg,且连续2小时尿量≥0.5 ml/kg/h,或血清乳酸较基线下降≥10%。

处置流程与药物剂量

  • 早期去甲肾上腺素组:在诊断后早期给予低剂量去甲肾上腺素(原文未写明具体剂量、给药途径和频次)。
  • 标准治疗组:按标准治疗(原文未写明具体方案)。

研究设计与关键结果

  • 研究类型:单中心、随机、双盲、安慰剂对照II期临床试验(CENSER trial,NCT01945983),在泰国Siriraj医院开展。
  • 样本量与分组:共310例脓毒症伴低血压成人,随机分为早期去甲肾上腺素组(n=155)和标准治疗组(n=155)。
  • 主要终点:6小时休克控制率早期去甲肾上腺素组118/155(76.1%)vs 标准治疗组75/155(48.4%),P<0.001。
  • 关键次要终点:28天死亡率早期去甲肾上腺素组24/155(15.5%)vs 标准治疗组34/155(21.9%),P=0.15,无显著差异。
  • 不良事件:心源性肺水肿早期去甲肾上腺素组22/155(14.4%)vs 标准治疗组43/155(27.7%),P=0.004;新发心律失常早期去甲肾上腺素组17/155(11%)vs 标准治疗组31/155(20%),P=0.03。
  • 给药时间:从急诊室到达至去甲肾上腺素给药的中位时间早期去甲肾上腺素组93 min vs 标准治疗组192 min,P<0.001。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照II期临床试验。
  • 局限:作者结论指出,将此方法引入临床复苏实践前需进一步研究。

对床旁实践的改变

  • 作者认为,早期去甲肾上腺素与6小时休克控制率增加显著相关,但进一步研究前不应将此方法引入临床复苏实践。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: Recent retrospective evidence suggests the efficacy of early norepinephrine administration during resuscitation; however, prospective data to support this assertion are scarce. Objectives: To conduct a phase II trial evaluating the hypothesis that early low-dose norepinephrine in adults with sepsis with hypotension increases shock control by 6 hours compared with standard care. Methods: This single-center, randomized, double-blind, placebo-controlled clinical trial was conducted at Siriraj Hospital, Bangkok, Thailand. The study enrolled 310 adults diagnosed with sepsis with hypotension. The patients were randomly divided into two groups: early norepinephrine (n = 155) and standard treatment (n = 155). The primary outcome was shock control rate (defined as achievement of mean arterial blood pressure ≥65 mm Hg, with urine flow ≥0.5 ml/kg/h for 2 consecutive hours, or decreased serum lactate ≥10% from baseline) by 6 hours after diagnosis. Measurements and Main Results: The patients in both groups were well matched in background characteristics and disease severity. Median time from emergency room arrival to norepinephrine administration was significantly shorter in the early norepinephrine group (93 vs. 192 min; P < 0.001). Shock control rate by 6 hours was significantly higher in the early norepinephrine group (118/155 [76.1%] vs. 75/155 [48.4%]; P < 0.001). The 28-day mortality was not different between groups: 24/155 (15.5%) in the early norepinephrine group versus 34/155 (21.9%) in the standard treatment group (P = 0.15). The early norepinephrine group was associated with lower incidences of cardiogenic pulmonary edema (22/155 [14.4%] vs. 43/155 [27.7%]; P = 0.004) and new-onset arrhythmia (17/155 [11%] vs. 31/155 [20%]; P = 0.03). Conclusions: Early norepinephrine was significantly associated with increased shock control by 6 hours. Further studies are needed before this approach is introduced in clinical resuscitation practice. Clinical trial registered with www.clinicaltrials.gov (NCT01945983) (CENSER trial).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Permpikul C, Tongyoo S, Viarasilpa T, et al. Early Use of Norepinephrine in Septic Shock Resuscitation (CENSER). A Randomized Trial. Am J Respir Crit Care Med. 2019. PMID: 30704260. doi:10.1164/rccm.201806-1034OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。